Literature DB >> 10433937

Overexpression of thrombospondin-1 decreases angiogenesis and inhibits the growth of human cutaneous squamous cell carcinomas.

M Streit1, P Velasco, L F Brown, M Skobe, L Richard, L Riccardi, J Lawler, M Detmar.   

Abstract

The function of the endogenous angiogenesis inhibitor thrombospondin-1 (TSP-1) in epithelial tumor development has remained controversial. We studied the in vitro growth characteristics and the in vivo tumor xenograft growth of the human squamous cell carcinoma cell lines A431 and SCC-13, stably transfected to overexpress human TSP-1. Overexpression of TSP-1 inhibited tumor growth of A431 xenotransplants, and completely abolished tumor formation by SCC-13 cells. TSP-1 overexpressing A431 tumors were characterized by extensive areas of necrosis and by decreased tumor vessel number and size. The effects of TSP-1 on tumor cell growth were indirect since tumor cell proliferation rates in vivo and in vitro, anchorage-dependent and -independent growth in vitro, and susceptibility to induction of apoptosis by serum withdrawal were unchanged in TSP-1 overexpressing tumor cells. However, TSP-1 overexpression up-regulated the TSP-1 receptor CD36, leading to enhanced adhesion of A431 cells to TSP-1. These findings establish TSP-1 as a potent inhibitor of angiogenesis and tumor growth in carcinomas of the skin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10433937      PMCID: PMC1866855          DOI: 10.1016/S0002-9440(10)65140-1

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  47 in total

1.  Thrombospondin binding by human squamous carcinoma and melanoma cells: relationship to biological activity.

Authors:  B L Riser; J Varani; K O'Rourke; V M Dixit
Journal:  Exp Cell Res       Date:  1988-02       Impact factor: 3.905

2.  Determination of cell number in monolayer cultures.

Authors:  R J Gillies; N Didier; M Denton
Journal:  Anal Biochem       Date:  1986-11-15       Impact factor: 3.365

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Light microscopic immunolocation of thrombospondin in human tissues.

Authors:  T N Wight; G J Raugi; S M Mumby; P Bornstein
Journal:  J Histochem Cytochem       Date:  1985-04       Impact factor: 2.479

5.  Tumor type-specific differences in cell-substrate adhesion among human tumor cell lines.

Authors:  J Varani; T E Carey; S E Fligiel; P E McKeever; V Dixit
Journal:  Int J Cancer       Date:  1987-03-15       Impact factor: 7.396

6.  Thrombospondin-induced attachment and spreading of human squamous carcinoma cells.

Authors:  J Varani; V M Dixit; S E Fligiel; P E McKeever; T E Carey
Journal:  Exp Cell Res       Date:  1986-12       Impact factor: 3.905

7.  Characterization of thrombospondin synthesis, secretion and cell surface expression by human tumor cells.

Authors:  J Varani; B L Riser; L A Hughes; T E Carey; S E Fligiel; V M Dixit
Journal:  Clin Exp Metastasis       Date:  1989 May-Jun       Impact factor: 5.150

8.  Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis.

Authors:  N Sheibani; W A Frazier
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

9.  Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis.

Authors:  D L Weinstat-Saslow; V S Zabrenetzky; K VanHoutte; W A Frazier; D D Roberts; P S Steeg
Journal:  Cancer Res       Date:  1994-12-15       Impact factor: 12.701

10.  Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1.

Authors:  P Bornstein
Journal:  J Cell Biol       Date:  1995-08       Impact factor: 10.539

View more
  86 in total

Review 1.  Thrombospondins as matricellular modulators of cell function.

Authors:  P Bornstein
Journal:  J Clin Invest       Date:  2001-04       Impact factor: 14.808

2.  Cloning and identification of a cDNA that encodes a novel human protein with thrombospondin type I repeat domain, hPWTSR.

Authors:  Jin-Zhong Chen; Shu Wang; Rong Tang; Quan-Sheng Yang; Enpeng Zhao; Yaoqiong Chao; Kang Ying; Yi Xie; Yu-Min Mao
Journal:  Mol Biol Rep       Date:  2002-09       Impact factor: 2.316

3.  Overexpression of the RNA binding protein HuR impairs tumor growth in triple negative breast cancer associated with deficient angiogenesis.

Authors:  Matthew M Gubin; Robert Calaluce; J Wade Davis; Joseph D Magee; Connie S Strouse; Daniel P Shaw; Lixin Ma; Ashley Brown; Timothy Hoffman; Tammy L Rold; Ulus Atasoy
Journal:  Cell Cycle       Date:  2010-08-17       Impact factor: 4.534

Review 4.  CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest.

Authors:  E Sick; A Jeanne; C Schneider; S Dedieu; K Takeda; L Martiny
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

Review 5.  Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization.

Authors:  Andrew J Sawyer; Themis R Kyriakides
Journal:  Adv Drug Deliv Rev       Date:  2016-01-04       Impact factor: 15.470

6.  Continuous administration of the three thrombospondin-1 type 1 repeats recombinant protein improves the potency of therapy in an orthotopic human pancreatic cancer model.

Authors:  Xuefeng Zhang; Caitlin Connolly; Mark Duquette; Jack Lawler; Sareh Parangi
Journal:  Cancer Lett       Date:  2006-06-06       Impact factor: 8.679

Review 7.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

8.  NFATc1 regulates lymphatic endothelial development.

Authors:  Rishikesh M Kulkarni; James M Greenberg; Ann L Akeson
Journal:  Mech Dev       Date:  2009-02-20       Impact factor: 1.882

9.  Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor.

Authors:  J C Rodriguez-Manzaneque; T F Lane; M A Ortega; R O Hynes; J Lawler; M L Iruela-Arispe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

Review 10.  Thrombospondin and apoptosis: molecular mechanisms and use for design of complementation treatments.

Authors:  Y Mirochnik; A Kwiatek; O V Volpert
Journal:  Curr Drug Targets       Date:  2008-10       Impact factor: 3.465

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.